607739-55-9

Upstream product

• 607739-49-1 5-[3,5-bis(trifluoromethyl)benzyl]-7-(2-methylphenyl)-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]-1,5-oxazocin-6-one 
• 544671-78-5 2-chloro-4-iodo-3-pyridinecarboxylic acid 
• 607739-45-7 5-[3,5-bis(trifluoromethyl)benzyl]-7-chloro-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]-1,5-oxazocin-6-one 
• 544671-79-6 N-[3,5-bis(trifluoromethyl)benzyl]-2-chloro-N-(3-hydroxypropyl)-4-iodo-3-pyridinecarboxamide 
• 78607-36-0 2-chloro-3-iodopyridine 

Downstream Products

• 607739-61-7 5-[3,5-bis(trifluoromethyl)benzyl]-9-chloro-7-(2-methylphenyl)-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]-1,5-oxazocin-6-one 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9- tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists

A series of novel bicyclic pyrimidine derivatives was prepared as part of a search for NK1 antagonist aimed at the treatment of urinary incontinence. Among them, 3g, a pyrimido[4,5-b][1,5]oxazocine derivative, bearing a 4-acetylpiperazinyl grou

Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H- pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK1 antagonists

Novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones were designed and prepared as part of a search for NK1 antagonists. Structure-activity relationship studies indicated that the conformational restri